Globus Medical, Inc. Q2 FY26 Results — Earnings Call Analysis
Published 30 May 2026 | Health Care Equipment and Supplies | Market Cap: ₹11.2K Cr
- U.S. - Globus Medical reiterated full-year 2026 revenue guidance of $3.18 billion to $3.22 billion, implying 8.2% to 9.6% growth over 2025.
From Globus Medical, Inc.'s Q2 FY26 earnings-call transcript · updated 30 May 2026.
Price
₹82.45
Market Cap
₹11.2K Cr
P/E Ratio
19.9
Revenue Rank
Margin Rank
How does Globus Medical, Inc. rank in Health Care Equipment and Supplies?
Compare Globus Medical, Inc. against every Health Care Equipment and Supplies company this quarter on revenue, margins and earnings-call signals.
📊 Revenue & Sales Performance
Rank 3- →U.S. Spine business expected to continue strong growth, with recent quarters showing around 10% growth, driven mainly by market share gains.
- →International Spine business targeting a return to consistent low double-digit growth (around 10% constant currency), with mid-teens growth seen recently influenced by currency and prior-year supply chain disruptions. Long term, international growth expected in the low to mid-double-digit range (12%-15%), focusing on deeper market penetration rather than expanding into new countries.
- →Enabling Technologies business growing, with 21% revenue increase in Q1 2026, but shifting to more flexible offerings (leases/rentals) possibly moderating upfront revenue recognition.
- →Trauma and neuromonitoring businesses showing strong growth (over 30%).
- →Overall guidance for 2026 revenue reaffirmed at $3.18B to $3.22B, implying 8.2% to 9.6% growth over 2025.
- →Long-term goal is sustainable, profitable growth supported by innovation, increased R&D, and operational efficiencies.
📈 Profitability & Margins
Rank 1- →Globus Medical reiterated full-year 2026 revenue guidance of $3.18 billion to $3.22 billion, implying 8.2% to 9.6% growth over 2025.
- →Non-GAAP diluted EPS guidance was raised to $4.70 to $4.80 from $4.40 to $4.50, implying 18.1% to 20.6% growth over 2025.
- →EPS growth is driven by margin expansion (gross profit margin sustained above 69% in Q1) and operating leverage from sales growth.
- →Management expects continued gross margin improvements, targeting mid-70% gross margin long term with ongoing supply chain and manufacturing initiatives.
- →While top-line growth is expected at high single digits long-term, bottom-line (EPS) growth is expected to outpace revenue growth.
- →R&D spending will increase, especially in Spine and Enabling Technologies, which may modestly offset some margin gains.
- →No specific 2027 guidance is provided, but strategic focus remains on sustainable, profitable double-digit EPS growth.
🏗️ Capital Expenditure Plans
Yes- →Capital expenditures were $39.6 million in the recent quarter, representing 5.2% of sales.
- →Capital allocation priorities remain:
- → - Internal investment in innovative product development.
- → - Capital spending on building sets for global sales force.
- → - Investments in facilities, machinery, and equipment to expand manufacturing footprint.
- →Continued share repurchase program with $390 million remaining authorized as of March 31, 2026.
- →Ongoing evaluation of complementary M&A focused on investments driving long-term profitable growth.
- →Increased focus on R&D spending, especially doubled investment in Spine and Enabling Technologies.
- →Emphasis on supply chain initiatives to improve cost efficiency and support margin expansion.
💰 Fundraising & Capital Structure
No information- →No indication of new fundraising through debt or equity in the current quarter.
- →Company has $799.3 million in cash, cash equivalents, and marketable securities as of March 31, 2026.
- →Existing share repurchase program of $500 million initiated in Q2 2025; $110 million purchased so far with $390 million remaining.
- →Capital allocation priorities include internal investment in product development, supporting sales force expansion, manufacturing investments, share repurchases, and evaluating complementary M&A.
- →No new debt issuance mentioned; paydown of $450 million convertible debt occurred in Q1 2025.
- →Focus remains on organic growth and strategic uses of capital rather than new debt or equity fundraising at this time.
📋 Order Book & Pipeline
No informationKey Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Continue your research
Others in Health Care Equipment and Supplies this season
- Insulet Corporation (Q2 FY26)
Insulet Corporation Q2 FY26 quarterly results analysis. Full year 2026 total company revenue growth guidance raised to 21%-23%; Omnipod revenue growth of 22%-24
- Align Technology, Inc. (Q2 FY26)
Align Technology, Inc. Q2 FY26 quarterly results analysis. Worldwide revenue growth for full-year 2026 is expected to be up 3% to 4% year-over-year. Market Cap
- Solventum Corporation (Q2 FY26)
Solventum Corporation Q2 FY26 quarterly results analysis. Expectation of improved growth in 2026 compared to 2025, supporting trajectory toward LRP targets (Pag
- Zimmer Biomet Holdings, Inc. (Q2 FY26)
Zimmer Biomet Holdings, Inc. Q2 FY26 quarterly results analysis. U.S. Market Cap $16,023, P/E 21.9. AI-powered earnings insights.
Frequently Asked Questions
What were Globus Medical, Inc. Q2 FY26 results?
- U.S. - Globus Medical reiterated full-year 2026 revenue guidance of $3.18 billion to $3.22 billion, implying 8.2% to 9.6% growth over 2025.
What is Globus Medical, Inc. share price analysis?
Globus Medical, Inc. currently shows a below-average growth signal. The stock trades at a P/E of 19.9 with a market cap of $11,192. Investors should review the full earnings analysis for detailed insights.
Is Globus Medical, Inc. planning capital expenditure?
- Capital expenditures were $39.6 million in the recent quarter, representing 5.2% of sales.
Keep Globus Medical, Inc. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.